Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Terminated 2Unknown 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Lymphoma 223Lymphoma, Large B-Cell, Diffuse 208Lymphoma, Non-Hodgkin 148Leukemia, Lymphocytic, Chronic, B-Cell 138Lymphoma, Follicular 130Lymphoma, Mantle-Cell 117Lymphoma, B-Cell, Marginal Zone 78Leukemia 72Burkitt Lymphoma 62Waldenstrom Macroglobulinemia 57Precursor Cell Lymphoblastic Leukemia-Lymphoma 46Lymphoma, B-Cell 45Recurrence 39Lymphoma, Large-Cell, Immunoblastic 33Hodgkin Disease 26Neoplasms 16Dendritic Cell Sarcoma, Interdigitating 16Lymphoma, Large-Cell, Anaplastic 14Leukemia, Myeloid, Acute 14Myelodysplastic Syndromes 12Leukemia, Hairy Cell 12Multiple Myeloma 11Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9Hematologic Neoplasms 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia, Prolymphocytic 8Leukemia, Myeloid, Accelerated Phase 8Intraocular Lymphoma 8Neoplasms, Plasma Cell 7Leukemia, Myelomonocytic, Chronic 7

Interventions

Cyclophosphamide 6Rituximab 3isatuximab 2fludarabine phosphate 2fludarabine 2durvalumab 2anlotinib 2Whole-Body Irradiation 2Vincristine 2Tacrolimus 2Sunitinib 2Prednisone 2Peripheral Blood Stem Cell Transplantation 2Pemetrexed 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Mesna 2Melphalan 2Lenalidomide 2Gemcitabine 2Doxorubicin 2Dexamethasone 2Cisplatin 2Carboplatin 2Busulfan 2Bevacizumab 2130-nm albumin-bound paclitaxel 2ponatinib 1pomalidomide 1penpulimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms by Histologic Type × Rituximab × Clear all
NCT05186558 2022-03-07

Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Unknown
54 enrolled
Lymphoid

Neoplasms by Histologic Type, Lymphoma, Large B-Cell, Diffuse

NCT02592876 2019-05-17

Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma

Seagen Inc.

Phase 2 Terminated
81 enrolled 15 charts
Lymphoid

Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02855359 2019-03-11

Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

Seagen Inc.

Phase 2 Terminated
24 enrolled 10 charts
Lymphoid

Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡